The Notes, which are senior unsecured in nature, will be issued by Pfizer Investment Enterprises Pte. Ltd. The proposed acquisition of Seagen Inc. by Pfizer will be paid for with the net proceeds of the offering.
On May 19, 2023, the offering is anticipated to close. Goldman Sachs, Citigroup, BofA Securities, and JP Morgan are among the top financial institutions.
Offering Price
Morgan is serving as the offering’s joint lead manager and book-running manager. No securities, including the Notes, are being offered for sale or purchased in connection with this press release.
Pfizer works hard to establish the benchmark for quality, safety, and value in the research, development, and production of medical products. Future-Looking Remarks This press release might contain predictions made in accordance with Sections 27A and 21E of the Securities Act of 1933, as amended.
- On May 19, 2023, the offering is anticipated to close.
- Morgan is serving as the offering’s joint lead manager and book-running manager.
- Actual outcomes could be very different from both historical and projected outcomes.
In this news release, there are comments about the anticipated terms of the Notes issuance, the use of proceeds to fund a portion of the Merger consideration, and the closure date that constitute forward-looking information.
Risks, uncertainties, and other issues are listed in Pfizer’s Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Actual outcomes could be very different from both historical and projected outcomes.
Except as required by law or the SEC’s rules and regulations, the company makes no commitment to publicly update any forward-looking information. Investors are recommended to review any additional disclosures they make in their Form 10-K, Form 10-Q, Form 8-K, and other SEC filings.
There is no prospectus, offering circular, or other document registered with the Singaporean Monetary Authority.
